All Tables |
---|
Table 1. | Outline of the Guidelines Development Process |
Table 2. | Rating Scheme for Recommendations |
Table 3. | Laboratory Monitoring Schedule for Patients Prior to and After Initiation of Antiretroviral Therapy |
Table 4. | Recommendations for Using Drug-Resistance Assays |
Table 5a. | Preferred and Alternative Antiretroviral Regimens for Antiretroviral Therapy-Naive Patients |
Table 5b. | Acceptable Antiretroviral Regimens for Treatment-Naive Patients |
Table 6. | Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy |
Table 7. | Antiretroviral Components Not Recommended as Initial Therapy |
Table 8. | Antiretroviral Regimens or Components That Should Not Be Offered At Any Time |
Table 9a. | Trough Concentrations of Antiretroviral Drugs for Patients Who Have Drug-Susceptible Virus |
Table 9b. | Trough Concentrations of Antiretroviral Drugs for Treatment-Experienced Patients with Virologic Failure |
Table 10. | Identifying, Diagnosing, and Managing Acute HIV-1 Infection |
Table 11. | Drug Interactions between Antiretroviral Agents and Drugs Used to Treat Opioid Addiction |
Table 12. | Strategies to Improve Adherence to Antiretroviral Therapy |
Table 13. | Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects |
Table 14. | Drugs That Should Not Be Used with PI, NNRTI, or CCR5 Antagonist |
Table 15a. | Drug Interactions between PIs and Other Drugs |
Table 15b. | Drug Interactions between NNRTIs and Other Drugs |
Table 15c. | Drug Interactions between NRTIs and Other Drugs (Including ARV Agents) |
Table 15d. | Drug Interactions between CCR5 Antagonist and Other Drugs |
Table 15e. | Drug Interactions between Integrase Inhibitor and Other Drugs |
Table 16a. | Interactions among PIs |
Table 16b. | Interactions between NNRTIs, MVC, RAL, and PIs |
Appendix B |
---|
Table 1. | Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) |
Table 2. | Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) |
Table 3. | Characteristics of Protease Inhibitors (PIs) |
Table 4. | Characteristics of Integrase Inhibitor |
Table 5. | Characteristics of Fusion Inhibitor |
Table 6. | Characteristics of CCR5 Antagonist |
Table 7. | Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency |